William D. Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, gives an overview of tenosynovial giant cell tumors (TGCT).
As Dr. Tap explains, TGCT are a group of rare, benign tumors that involve the synovium, bursae and tendon sheath. While these tumors are benign, they can grow and cause extreme damage to the surrounding tissues. There are generally two types of TGCT, a nodular form that typically can be treated with surgical removal of the tumor, and a more diffuse form that will require medical therapy. For the latter diffuse type of TGCT, the FDA-approved CSF1R inhibitor, pexidartinib, can be effective.
To learn more about this rare disease, visit our TGCT Learning Center here.
